|
MechanismSARS-CoV-2 Mpro inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Into Oregon State University, Inc.
0 Patents (Medical) associated with Into Oregon State University, Inc.
100 Deals associated with Into Oregon State University, Inc.
100 Translational Medicine associated with Into Oregon State University, Inc.